ArticleAnnals of surgical treatment and research2019
Long-term postresection prognosis of primary neuroendocrine tumors of the liver.
Article in Annals of surgical treatment and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Primary Hepatic Neuroendocrine Neoplasms: Systematic Review and Expert Pathologist Reappraisal Using the WHO 6th Edition Framework.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Clinical analysis of seven cases of primary hepatic neuroendocrine neoplasms.Frontiers in oncology · 2026Article
- Case report: Recurrence of primary hepatic neuroendocrine tumors after resection of liver segments IV in 8 years follow-up.Frontiers in medicine · 2024Article
- A rare primary hepatic neuroendocrine tumour with laparoscopic resection: a case report.Journal of medical case reports · 2023Article
- Potential effective diagnostic biomarker in patients with primary and metastatic small intestinal neuroendocrine tumors.Frontiers in genetics · 2023Article
- Diagnostic problem of Primary Hepatic Neuroendocrine Tumor in 18-year-old woman: A case report.International journal of surgery case reports · 2022Article
- Primary Hepatic Neuroendocrine Tumor Arising at a Young Age: Rare Case Report and Literature Review.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Review
- Developing a competing risk nomogram that predicts the survival of patients with a primary hepatic neuroendocrine tumor.Frontiers in medicine · 2022Article
- Cystic Primary Hepatic Neuroendocrine Tumor.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2021Article
- A case of laparoscopic hepatectomy for a primary hepatic neuroendocrine tumor.Clinical journal of gastroenterology · 2021Article
- Clinicopathological Characteristics and Survival Outcomes of Primary Hepatic Neuroendocrine Tumor: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary hepatic neuroendocrine tumor (PHNET) is a very rare neoplasm, requiring strict exclusion of metastasis from possible extrahepatic primary sites for its diagnosis.
methodsWe reviewed our clinical experience of 13 patients with primary hepatic NET who underwent liver resection from January 1997 to December 2015.
resultsThe mean age of the 13 patients (8 males and 5 females) was 51.1 ± 12.8 years; the most common clinical manifestation was vague, nonspecific abdominal pain (n = 9). Of them, 11 patients underwent preoperative liver biopsy, 7 of which correctly diagnosed as neuroendocrine tumor (NET). Ten patients underwent R0 resection, and 3 underwent R1 resection. Diagnosis of PHNET was confirmed both immunohistochemically and by absence of extrahepatic primary sites. All tumors were single lesions, with a mean size of 9.6 ± 7.6 cm and a median size of 4.3 cm; all showed positive staining for synaptophysin and chromogranin. During a mean follow-up period of 95.1 ± 86.6 months, 7 patients died from tumor recurrence, whereas the other 6 remain alive to date, making the 5-year tumor recurrence rate 56.0% and the 5-year patient survival rate 61.5%. When confined to R0 resection, 5-year recurrence and survival rates were 42.9% and 70.0%, respectively. Univariate analysis showed that Ki-67 proliferative index was the only risk factor for tumor recurrence.
conclusionPHNET is a very rare tumor with no specific clinical features, and its final diagnosis depends primarily on pathology, immunohistochemistry, and exclusion of metastasis from other sites. Aggressive surgical treatment is highly recommended for PHNET because of acceptably favorable postresection outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.